secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001651308-23-000066
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q1 product revenue $410.3M (+57% YoY); BRUKINSA sales double to $211.4M
-------------------------------------------------------------------------------

- Net loss narrowed to $348.4M ($0.26 per share) from $435.2M a year ago; operating leverage improved.
- Global BRUKINSA sales of $211.4M, up 103% YoY, driven by U.S. CLL/SLL launch ($138.8M U.S.).
- Tislelizumab revenue in China $114.9M (+31% YoY); 10 approved indications in China.
- Cash and short-term investments $3.8B as of March 31, 2023; operating cash outflow $563.8M in Q1.
- R&D expenses $408.6M; SG&A $328.5M; gross margin improved to 80.1% from 75.1%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/0001651308-23-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/bgne-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer